Detalles de la búsqueda
1.
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Blood
; 137(22): 3027-3036, 2021 06 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739404
2.
A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
Haematologica
; 2023 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37981892
3.
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV.
Hematol Oncol
; 40(5): 846-856, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35854643
4.
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Haematologica
; 105(7): 1937-1947, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31582542
5.
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
Cancer
; 124(10): 2228-2237, 2018 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29499087
6.
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.
Haematologica
; 102(11): 1931-1935, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28775121
7.
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Ann Hematol
; 96(12): 2071-2078, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29063955
8.
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
Am J Hematol
; 92(1): 82-87, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27770583
9.
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
Ann Hematol
; 93(1): 123-8, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23864035
10.
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
Am J Hematol
; 89(12): 1085-91, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25159313
11.
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.
Ann Hematol
; 92(9): 1271-80, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23660628
12.
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted.
Biomark Res
; 11(1): 29, 2023 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36894973
13.
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma.
Ann Hematol
; 91(3): 419-26, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21901342
14.
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.
Ann Hematol
; 91(6): 875-88, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22476884
15.
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
J Clin Oncol
; 40(27): 3120-3131, 2022 09 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35666982
16.
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia.
Blood Adv
; 6(6): 1742-1753, 2022 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34649276
17.
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Lancet
; 376(9758): 2075-85, 2010 Dec 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-21146205
18.
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
Blood
; 114(9): 1729-35, 2009 Aug 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-19561323
19.
Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study.
Transplant Cell Ther
; 27(3): 244.e1-244.e8, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33781522
20.
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study.
Leuk Lymphoma
; 62(8): 1897-1906, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33733993